Cano E - Search Results

1

Novel compounds of hybrid structure pyridazinone-coumarin as potent inhibitors of platelet aggregation.

Costas-Lago MC, Besada P, Cano E, Terán C. Costas-Lago MC, et al. Among authors: cano e. Future Med Chem. 2019 Aug;11(16):2051-2062. doi: 10.4155/fmc-2018-0373. Future Med Chem. 2019. PMID: 31538518

2

New platelet aggregation inhibitors based on pyridazinone moiety.

Costas T, Costas-Lago MC, Vila N, Besada P, Cano E, Terán C. Costas T, et al. Among authors: cano e. Eur J Med Chem. 2015 Apr 13;94:113-22. doi: 10.1016/j.ejmech.2015.02.061. Epub 2015 Mar 3. Eur J Med Chem. 2015. PMID: 25757094

3

Pyridazines. Part XXIX: synthesis and platelet aggregation inhibition activity of 5-substituted-6-phenyl-3(2H)-pyridazinones. Novel aspects of their biological actions.

Sotelo E, Fraiz N, Yáñez M, Terrades V, Laguna R, Cano E, Raviña E. Sotelo E, et al. Among authors: cano e. Bioorg Med Chem. 2002 Sep;10(9):2873-82. doi: 10.1016/s0968-0896(02)00146-3. Bioorg Med Chem. 2002. PMID: 12110307

4

Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity.

Coelho A, Raviña E, Fraiz N, Yáñez M, Laguna R, Cano E, Sotelo E. Coelho A, et al. Among authors: cano e. J Med Chem. 2007 Dec 27;50(26):6476-84. doi: 10.1021/jm061401d. Epub 2007 Nov 22. J Med Chem. 2007. PMID: 18031002

5

Design, synthesis, and vasorelaxant and platelet antiaggregatory activities of coumarin-resveratrol hybrids.

Vilar S, Quezada E, Santana L, Uriarte E, Yánez M, Fraiz N, Alcaide C, Cano E, Orallo F. Vilar S, et al. Among authors: cano e. Bioorg Med Chem Lett. 2006 Jan 15;16(2):257-61. doi: 10.1016/j.bmcl.2005.10.013. Epub 2005 Nov 3. Bioorg Med Chem Lett. 2006. PMID: 16275073

6

AM1 theoretical study, synthesis and biological evaluation of some benzofuran analogues of anti-inflammatory arylalkanoic acids.

Santana L, Teijeira M, Uriarte E, Teran C, Liñares B, Villar R, Laguna R, Cano E. Santana L, et al. Among authors: cano e. Eur J Pharm Sci. 1999 Jan;7(2):161-6. doi: 10.1016/s0928-0987(98)00019-0. Eur J Pharm Sci. 1999. PMID: 9845801

7

Pyridazines. Part 28: 5-alkylidene-6-phenyl-3(2H)-pyridazinones, a new family of platelet aggregation inhibitors.

Sotelo E, Fraiz N, Yáñez M, Laguna R, Cano E, Brea J, Raviña E. Sotelo E, et al. Among authors: cano e. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1575-7. doi: 10.1016/s0960-894x(02)00246-9. Bioorg Med Chem Lett. 2002. PMID: 12039565

8

Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones.

Crespo A, Meyers C, Coelho A, Yáñez M, Fraiz N, Sotelo E, Maes BU, Laguna R, Cano E, Lemière GL, Raviña E. Crespo A, et al. Among authors: cano e. Bioorg Med Chem Lett. 2006 Feb 15;16(4):1080-3. doi: 10.1016/j.bmcl.2005.10.073. Epub 2005 Nov 14. Bioorg Med Chem Lett. 2006. PMID: 16290144

9

Discovery and preliminary SAR of 5-arylidene-2,2-dimethyl-1,3-dioxane- 4,6-diones as platelet aggregation inhibitors.

El Maatougui A, Azuaje J, Coelho A, Cano E, Yañez M, López C, Yaziji V, Carbajales C, Sotelo E. El Maatougui A, et al. Among authors: cano e. Comb Chem High Throughput Screen. 2012 Aug;15(7):551-4. doi: 10.2174/138620712801619122. Comb Chem High Throughput Screen. 2012. PMID: 22272691

10

Pyridazines. Part 36: Synthesis and antiplatelet activity of 5-substituted-6-phenyl-3(2H)-pyridazinones.

Coelho A, Sotelo E, Fraiz N, Yáñez M, Laguna R, Cano E, Raviña E. Coelho A, et al. Among authors: cano e. Bioorg Med Chem Lett. 2004 Jan 19;14(2):321-4. doi: 10.1016/j.bmcl.2003.11.009. Bioorg Med Chem Lett. 2004. PMID: 14698150

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

249 results

Search Page